热门资讯> 正文

GT Bizerma报告第二季度业绩

2026-08-14 20:10

GT Biopharma Inc(GTBP) 0

GT Biopharma press release (GTBP): Q2 net loss for the second quarter of 2026 of approximately $4.5 million, compared to $30.2 million for the same comparable quarter of 2025.
The Company had cash and cash equivalents of approximately $5.1 million as of June 30, 2026, which is anticipated to be sufficient to fund the Company’s operations through the fourth quarter of 2026.

More on GT Biopharma

Seeking Alpha’s Quant Rating on GT Biopharma
Historical earnings data for GT Biopharma
Financial information for GT Biopharma

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。